|Day Low/High||2.00 / 2.25|
|52 Wk Low/High||4.08 / 15.01|
Here's a technical look at how to trade some of the most active stocks on the market right now.
Doug Kass shares his thoughts on what goes on his best ideas list and what's still moving down.
In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.
But we remain committed to our position in TherapeuticsMD.
Novavax (NVAX) stock rating was reduced at several firms this morning after the company's RSV-F vaccine didn't achieve its primary and secondary endpoints in a clinical trial.
Here are Friday's top research calls, including downgrades for Citigroup and Novavax, an upgrade Comerica and new coverage of PepsiCo.
Novavax (NVAX) announced late Thursday that its RSV-F vaccine for lower respiratory tract disease did not meet its objectives in a clinical trial.
Cramer says McCormick is up too much and he's not chasing Clayton Williams Energy.
There are too many companies in just about every sector of this market, Cramer says.
Novavax (NVAX) reported a larger-than-anticipated loss and weak revenue for the 2016 second quarter.
Novavax (NVAX) revenue declined 82% year-over-year for the second quarter.
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Trade-Ideas LLC identified Novavax (NVAX) as a strong on high relative volume candidate
The markets took Friday's weak employment number pretty well, so Cramer's game plan focuses on a weaker U.S. dollar.
Cramer says VF is doing a terrific job but he's avoiding China Mobile.